Inductive Bio

Inductive Bio is an AI-powered virtual lab platform purpose-built for small molecule drug discovery. The company empowers medicinal chemistry teams to evaluate chemistry ideas at unprecedented scale by pairing scientists with AI-driven tools that can run millions of in silico experiments, predicting how molecules will behave in the body and surfacing the strongest hypotheses for wet lab testing. Inductive Bio serves leading biotechs and pharmaceutical organizations across a wide range of therapeutic areas and small molecule modalities.

Inductive Bio has established itself as a benchmark leader in ADMET prediction, winning consecutive first-place finishes in the world's largest blind ADMET competitions — including the OpenADMET 2026 challenge with ExpansionRx (over 370 submissions predicting up to 9 endpoints across more than 2,250 compounds) and the OpenADMET 2025 Polaris Ligand ADMET competition with ASAP (outperforming 38 competitors from leading AI drug discovery companies and academic groups). The company is also leading a $21M ARPA-H initiative alongside Amgen and top academic institutions to develop next-generation AI drug toxicity models for improved drug safety assessment.

Core Products and Platform

• Beacon-1 ADMET Models: Inductive Bio's flagship class of AI models built for real-world heterogeneous ADMET data. Beacon-1 is trained on a pre-competitive data consortium and can be fine-tuned to a customer's specific chemical space, delivering state-of-the-art prediction accuracy across a broad range of ADMET endpoints.
• Compass (Virtual Lab Bench): A software platform that gives chemistry teams direct access to run virtual experiments, review ADMET predictions, and make real-time decisions about which compounds to synthesize. Compass puts a virtual lab directly into the hands of the team to guide each design cycle toward the most promising compounds.
• Indy (AI Chemistry Assistant): An AI assistant that brings veteran chemistry expertise to automate time-consuming operations, help design and interpret experiments, and drive programs forward — effectively giving every chemist the output of an entire team.
• Digital Organs: Models trained on billions of unique data points generated from drug-organ interactions in relevant human biology, enabling prediction of a molecule's safety in humans long before entering the clinic.

Data Foundation and Scientific Approach

• Inductive Bio operates a rapidly growing pre-competitive ADMET data consortium that securely combines large, diverse datasets from across the industry, powering accurate predictions across broad chemical space.
• The consortium model allows even small biotech companies to leverage thousands of data points to drive the design of improved molecules.
• The platform is designed to front-load critical ADMET insights early in the design-make-test cycle, reducing the need for costly and time-consuming experimental measurements before synthesis decisions are made.
• Beacon-1 models support fine-tuning to a partner's specific chemical space, ensuring relevance and accuracy for individual programs.

Engagement Models and Services

• Compass Software: Teams can access the virtual lab directly through the Compass platform to independently guide design cycles and evaluate compound ideas in real time.
• Embedded Experts: Inductive Bio's own chemistry team can be brought in to operate the virtual lab alongside a partner's team, running experiments and delivering curated compound ideas tailored to the partner's design strategy.
• End-to-End Chemistry Partners: Inductive Bio partners with select CROs to synthesize and test the best compounds identified in the virtual lab, closing the loop between virtual and wet lab work in a tight, AI-informed feedback loop for full program acceleration.

Proven Results and Customer Impact

• Inductive Bio supports dozens of partners across therapeutic areas, with virtual labs advancing a wide range of small molecule modalities.
• Multiple programs guided by Inductive Bio's virtual labs have achieved development candidates.
• Partners report saving time and reducing costs by prioritizing the most viable, high-quality compounds for synthesis, making every design cycle more impactful.
• Customers have used Inductive Bio's solubility model to predict compound behavior in screening assays, speeding up design cycles by eliminating the wait for experimental solubility measurements.
• Integration of Inductive Bio's ADMET models into partner predictive platforms has enabled rapid iteration and optimization of lead compounds while addressing critical ADMET challenges.
• The platform has been praised for its user-friendly interface and its ability to help small biotech companies leverage large consortium datasets to drive molecule design improvements.

Inductive Bio combines benchmark-validated AI models, an intuitive virtual lab platform, and deep chemistry expertise to help drug discovery teams design higher-quality compounds faster — reducing costs, accelerating design cycles, and ultimately delivering better development candidates to the clinic.